DarioHealth Corp. 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by DarioHealth Corp. on March 1, 2024, reporting events occurring between February 15, 2024, and February 21, 2024. The Company is incorporated in Delaware and trades on The Nasdaq Capital Market under the symbol DRIO.
Key Financial Metrics
The filing details a completed equity offering with the following financial outcomes:
- Gross Proceeds: Approximately $22,422,000.
- Securities Issued:
- 17,307 shares of Series C Preferred Stock.
- 4,000 shares of Series C-1 Preferred Stock.
- 1,115 shares of Series C-2 Preferred Stock.
- Purchase Price: $1,000 per share for all classes of Preferred Stock.
- Placement Agent: Aegis Capital Corp.
The filing does not provide specific data regarding revenue, operating profit, cash flow, margins, or existing debt levels.
Material Changes
The primary material change is the successful closing of a private placement offering on February 21, 2024. This transaction significantly increased the Company's cash position through the issuance of new preferred equity. The Company explicitly stated it does not intend to conduct any further closings regarding this specific Offering.
Outlook and Risks
Management commentary is limited to the confirmation of the Offering's closure and the cessation of further closings for this tranche. The filing does not contain updated forward-looking guidance, specific risk factors, or discussion of contingencies beyond the standard execution of the securities purchase agreements with accredited investors.
Investor Verification Checklist
- Verify the specific rights, preferences, and liquidation priorities of the newly issued Series C, C-1, and C-2 Preferred Stock.
- Confirm the use of proceeds from the $22.4 million gross offering in subsequent filings or press releases.
- Review the Company's current cash runway and burn rate in the most recent 10-Q or 10-K to assess the impact of these proceeds on liquidity.
- Check for any dilution effects on common stockholders resulting from the conversion features of the new preferred shares.